Azelastine–fluticasone

A nasal spray combining azelastine (an antihistamine) and fluticasone (a corticosteroid), FDA-approved for seasonal allergic rhinitis in ages 6 and older.

psilodex.org/m/azelastine-fluticasone · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~25 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Azelastine–fluticasone”, v2026.10.05. psilodex.org/m/azelastine-fluticasone

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Sources [1]

FDA-approved for

Seasonal allergic rhinitis (ages 6 and older)

Sources [1]

01 Interaction with psilocybin

No psilocybin-specific interaction is known; its sleepiness may add to other sedating effects.

Detail Azelastine is a nasal antihistamine. Sleepiness (somnolence) was reported in some trial participants. The label states alcohol or other CNS depressants (sedating drugs) may further reduce alertness. Fluticasone is a nasal steroid with no known interaction. Sources [1]

Human data with psilocybin: No psilocybin data; based on its label
Half-life: Azelastine ~25 h; fluticasone ~7.8 h (IV dosing) (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

DYMISTA (azelastine HCl and fluticasone propionate) nasal spray (Viatris; NDA202236) · FDA label (DailyMed) — revised 2024-12-04 | "relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older" | Sedating or CNS depressant: 5.1 "additional reductions in alertness and additional impairment of central nervous system performance may occur" | "half-life of azelastine hydrochloride is approximately 25 hours"; fluticasone "terminal elimination half-life of approximately 7.8 hours"
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →